Login to Your Account



Tivozanib fails in colorectal cancer; Aveo takes a dive

By Catherine Shaffer
Staff Writer

Monday, December 16, 2013

The hits keep coming for Aveo Pharmaceuticals Inc., as its once-daily VEGF receptor tyrosine kinase inhibitor failed another indication, this time colorectal cancer (CRC). The Cambridge, Mass.-based biotech’s already beaten-down stock fell 9 percent on news that the drug, tivozanib, foundered during an interim analysis in the Phase II BATON-CRC study, being carried out in partnership with Astellas Pharma Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription